Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic progressive acquired neuropathy thought to be mediated by the immune system. The course of CIDP may be a stepwise or continuous worsening over months or years. Diagnosis is based on clinical symptoms and signs, neurophysiological studies, lumbar puncture, and cerebrospinal fluid examination that fulfil published criteria for CIDP.I Randomised controlled studies have documented that prednisone2 and plasma exchange3 are both beneficial and these two forms of therapy represent the mainstay of treatment for CIDP. Both treatments, however, have side effects and some patients do not respond to treatment. Approximately 95% of patients with CIDP initially respond to prednisone, but dose reduction frequently results in a relapse. 4 Plasma exchange is helpful in patients whose condition is deteriorating rapidly, in nonresponders to prednisone, and in patients who need to avoid prednisone. The beneficial effect of plasma exchange begins to fade 10 to 
